A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

December 19, 2023

Study Completion Date

December 7, 2024

Conditions
BRAF V600EMetastatic Colorectal Cancer
Interventions
DRUG

Encorafenib

oral hard capsule

DRUG

Cetuximab

intravenous infusion

DRUG

FOLFIRI

"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"

Trial Locations (34)

100036

Beijing Cancer Hospital, Beijing

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

110001

The First Hospital of China Medical University, Shenyang

110042

Liaoning Cancer Hospital & Institute, Shenyang

121011

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou

130021

The First Hospital of Jilin University, Changchun

150040

Harbin Medical University Cancer Hospital, Harbin

200032

Zhongshan Hospital Fudan University, Shanghai

200040

Huashan Hospital Fudan University, Shanghai

200092

Xinhua Hospital Affilliated to Shanghai Jiaotong University School of Medicine, Shanghai

200120

Shanghai East Hospital, Tongji University, Shanghai

213003

The First People's Hospital of Changzhou, Changzhou

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou

310016

Sir Run Run Shaw Hospital - Zhejiang University School of Medicine, Hangzhou

330006

The First Affiliated Hospital of Nanchang University, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

341001

First Affiliated Hospital of Gannan Medical University, Ganzhou

350014

Fujian Medical University - Fujian Provincial Cancer Hospital, Fuzhou

361001

The First Affiliated Hospital of Xiamen University, Xiamen

410008

Xiangya Hospital Central South University, Changsha

430022

Union Hospital Tongji medical college Huazhong University of Science and Technology, Wuhan

430030

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan

430071

Zhongnan Hospital of Wuhan University, Wuhan

450008

Henan Cancer Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510095

Cancer Center of Guangzhou Medical University, Guangzhou

510655

The Sixth Affiliated Hospital Sun Yat-Sen University, Guangzhou

515041

Cancer Hospital Affiliated to Shantou University Medical College, Shantou

518036

Peking University Shenzhen Hospital, Shenzhen

528010

The First People's Hospital of Foshan, Foshan

641000

The Second People's Hospital of Neijiang, Neijiang

710068

Shaanxi Provincial People's Hospital, Xi'an

071000

The Affiliated Hospital of Hebei University, Baoding

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Pierre Fabre Medicament

INDUSTRY

NCT05004350 - A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | Biotech Hunter | Biotech Hunter